Renal cell carcinoma recurrence after nephrectomy for localized disease: Predicting survival from time of recurrence

Scott E. Eggener, Ofer Yossepowitch, Joseph A. Pettus, Mark E. Snyder, Robert J. Motzer, Paul Russo

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Prognostic factors for patients with metastatic renal cell carcinoma (RCC) are well established. However, the risk profile is unknown for patients with recurrent RCC after a nephrectomy for localized disease. Patients and Methods: From January 1989 to July 2005, we identified patients with localized RCC treated by nephrectomy who subsequently developed recurrent disease. We applied a validated prognostic scoring system previously developed for patients with metastatic RCC. Each patient was given a total risk score of 0 to 5, with one point for each of five prognostic variables (recurrence < 12 months after nephrectomy, serum calcium > 10 mg/dL, hemoglobin < lower limit of normal, lactate dehydrogenase > 1.5x upper limit of normal, and Karnofsky performance status < 80%). Patients were categorized into low- (score = 0), intermediate- (score = 1 to 2), and high-risk subgroups (score = 3 to 5). Results: Our final cohort included 118 patients, with a median survival time of 21 months from the time of recurrence. Median follow-up time for survivors was 27 months. Overall survival was strongly associated with risk group category (P < .0001). Low-risk, intermediate-risk, and high-risk criteria were fulfilled in 34%, 50%, and 16% of patients, respectively. Median survival time for low-risk, intermediate-risk, and high-risk patients was 76, 25, and 6 months, respectively. Two-year overall survival rates for low-risk, intermediate-risk, and high-risk patients were 88% (95% CI, 77% to 99%), 51% (95% CI, 37% to 65%), and 11% (95% CI, 0% to 24%), respectively. Conclusion: At disease recurrence after nephrectomy for localized disease, a scoring system based on objective clinical and laboratory data provides meaningful risk stratification for both patient counseling and clinical trial entry.

Original languageEnglish
Pages (from-to)3101-3106
Number of pages6
JournalJournal of Clinical Oncology
Volume24
Issue number19
DOIs
StatePublished - 1 Jul 2006
Externally publishedYes

Fingerprint

Dive into the research topics of 'Renal cell carcinoma recurrence after nephrectomy for localized disease: Predicting survival from time of recurrence'. Together they form a unique fingerprint.

Cite this